Lan Deng

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Yu Wang, Xuejie Jiang, F. Huang, 2023, Journal of Internal Medicine.

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy

Hua Jin, Zhiqiang Sun, Guopan Yu, 2024, Cancer medicine.